Diffusion Pharma reports positive Altitude Trial results for TSC; appoints Raven Jaeger as CRO

CervoMed Inc.

TSC 2.5 mg/kg dose showed positive effects on pH (p<0.1 vs placebo) and lactate at end of exercise under simulated 15,000 ft hypoxia.
Post-exercise recovery improved for pH, lactate, and oxygen saturation (SpO2) at 10 minutes with 2.5 mg/kg dose.
TSC was safe and well tolerated with no serious adverse events across all doses.
Results support planned Phase 2 Hypoxic Tumor Trial initiation in H2 2022; discussions with FDA ongoing.
Employment agreement for CRO Raven Jaeger effective May 18, 2022 includes severance of 1.5x base salary + bonus upon change of control and 12-month non-compete.

item 1.01 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Raven Jaeger

Chief Regulatory Officer

CRVO · CervoMed Inc.

Effective: 2022-05-18
Filed: June 28, 2022, 7:59 PM ET

As previously disclosed, on May 18, 2022, Raven Jaeger, M.S., was appointed as the Chief Regulatory Officer of Diffusion Pharmaceuticals Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Raven Jaeger was appointed as Chief Regulatory Officer at CervoMed Inc..

Action: appointed
Role: Chief Regulatory Officer

Exact text from the filing

As previously disclosed, on May 18, 2022, Raven Jaeger, M.S., was appointed as the Chief Regulatory Officer of Diffusion Pharmaceuticals Inc.

View on SEC.gov

CervoMed Inc. filing history →

Source: SEC EDGAR

accession 0001437749-22-016082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.